|  | n | % |
---|---|---|---|
Medical characteristics | Cadaveric donor transplantation | 1035 | 97.5% |
Duration of transplantation, years | 8.5 ± 5.8 | ||
Patients with rejection since renal transplant | 222 | 22.9% | |
Major causes of ESRD | |||
Chronic glomerular nephritis | 380 | 35.8% | |
Interstitial nephropathy | 122 | 11.5% | |
Hereditary nephropathy | 206 | 19.4% | |
Duration of dialysis, months (mean ± SD) | 31.3 ± 37.2 | ||
Intercurrent health events in the last four weeks | 245 | 23.2% | |
Hospitalization | 111 | 11.1% | |
Critical illness | 47 | 4.7% | |
Infectious disease | 123 | 13.7% | |
Acute rejection episodes | 42 | 4.0% | |
Graft surgery | 17 | 1.9% | |
Comorbidities | |||
Hypertension | 844 | 80.9% | |
BMI > 30 (kg/m2) | 140 | 13.4% | |
Diabetes mellitus | 133 | 12.9% | |
Current smokers | 122 | 11.8% | |
Treatments, compliance and side | Side effects | 838 | 79% |
Mean number of side effects per patient | 5.7 ±3.9 | ||
Range | (1–17) | ||
Mean number of drugs per patient | 5.1 ±3.1 | ||
Immunosuppressive treatment | |||
Calcineurin inhibitors | 956 | 90.6% | |
Corticosteroids | 593 | 56.2% | |
Antimetabolites | 769 | 72.9% | |
Proliferation inhibitors | 53 | 5.0% | |
Monotherapy | 109 | 10.3% | |
Bitherapy | 564 | 53.5% | |
Tritherapy | 378 | 35.8% | |
Other treatment | |||
Antihypertensive drugs | 890 | 84.4% | |
Hypolipidemics | 540 | 51.2% | |
Antidiabetic agents | 100 | 9.5% | |
Non-compliant to treatment | 239 | 22.5% | |
Side effects related to: | |||
General health | 548 | 51.6% | |
Mental health | 467 | 44.0% | |
Body modification | 771 | 72.7% | |
Sexual disorders | 288 | 27.1% | |
 | Diarrhea | 216 | 20.4% |